Statins and cardiovascular risk in rheumatic diseases

Bianca Marasini, M. Massarotti

Research output: Contribution to journalArticle

Abstract

Chronic inflammatory rheumatic diseases are associated with an increased risk of cardiovascular (CV) atherosclerotic events. The inflammatory state, which is the hallmark of chronic rheumatic diseases, is the important driving force for accelerated atherogenesis. Since the control of traditional risk factors alone is insufficient in reducing the risk, much attention has been directed towards the potential use of statins. Statins, a family of drugs that suppress cholesterol biosynthesis by inhibiting the hydroxymethyl glutaryl coenzyme A reductase, have been shown to significantly reduce CV-related morbidity and mortality. In addition to lower lipid levels, several non-lipid lowering pleiotropic effects, including anti-inflammatory and immunomodulatory activities, make statins potential therapeutic agents in chronic rheumatic diseases. However, lipid metabolism in chronic rheumatic diseases is complex, since inflammatory states can induce alterations in lipid levels and function, so that cholesterol target levels from general guidelines may not be adequate in chronic inflammatory rheumatic diseases. Larger trials are needed to refine the precise benefits and health-utility associated with this therapy.

Original languageEnglish
Pages (from-to)25-30
Number of pages6
JournalInternational Journal of Immunopathology and Pharmacology
Volume25
Issue number1
Publication statusPublished - Jan 2012

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Rheumatic Diseases
Chronic Disease
Cholesterol
Lipids
Insurance Benefits
Lipid Metabolism
Atherosclerosis
Oxidoreductases
Anti-Inflammatory Agents
Guidelines
Morbidity
Mortality
Therapeutics
Pharmaceutical Preparations

Keywords

  • Cardiovascular risk
  • Rheumatic diseases
  • Statins

ASJC Scopus subject areas

  • Pharmacology
  • Immunology
  • Immunology and Allergy

Cite this

Statins and cardiovascular risk in rheumatic diseases. / Marasini, Bianca; Massarotti, M.

In: International Journal of Immunopathology and Pharmacology, Vol. 25, No. 1, 01.2012, p. 25-30.

Research output: Contribution to journalArticle

@article{2f7686162ec04defb51f379fc0a07220,
title = "Statins and cardiovascular risk in rheumatic diseases",
abstract = "Chronic inflammatory rheumatic diseases are associated with an increased risk of cardiovascular (CV) atherosclerotic events. The inflammatory state, which is the hallmark of chronic rheumatic diseases, is the important driving force for accelerated atherogenesis. Since the control of traditional risk factors alone is insufficient in reducing the risk, much attention has been directed towards the potential use of statins. Statins, a family of drugs that suppress cholesterol biosynthesis by inhibiting the hydroxymethyl glutaryl coenzyme A reductase, have been shown to significantly reduce CV-related morbidity and mortality. In addition to lower lipid levels, several non-lipid lowering pleiotropic effects, including anti-inflammatory and immunomodulatory activities, make statins potential therapeutic agents in chronic rheumatic diseases. However, lipid metabolism in chronic rheumatic diseases is complex, since inflammatory states can induce alterations in lipid levels and function, so that cholesterol target levels from general guidelines may not be adequate in chronic inflammatory rheumatic diseases. Larger trials are needed to refine the precise benefits and health-utility associated with this therapy.",
keywords = "Cardiovascular risk, Rheumatic diseases, Statins",
author = "Bianca Marasini and M. Massarotti",
year = "2012",
month = "1",
language = "English",
volume = "25",
pages = "25--30",
journal = "International Journal of Immunopathology and Pharmacology",
issn = "0394-6320",
publisher = "Biomedical Research Press s.a.s.",
number = "1",

}

TY - JOUR

T1 - Statins and cardiovascular risk in rheumatic diseases

AU - Marasini, Bianca

AU - Massarotti, M.

PY - 2012/1

Y1 - 2012/1

N2 - Chronic inflammatory rheumatic diseases are associated with an increased risk of cardiovascular (CV) atherosclerotic events. The inflammatory state, which is the hallmark of chronic rheumatic diseases, is the important driving force for accelerated atherogenesis. Since the control of traditional risk factors alone is insufficient in reducing the risk, much attention has been directed towards the potential use of statins. Statins, a family of drugs that suppress cholesterol biosynthesis by inhibiting the hydroxymethyl glutaryl coenzyme A reductase, have been shown to significantly reduce CV-related morbidity and mortality. In addition to lower lipid levels, several non-lipid lowering pleiotropic effects, including anti-inflammatory and immunomodulatory activities, make statins potential therapeutic agents in chronic rheumatic diseases. However, lipid metabolism in chronic rheumatic diseases is complex, since inflammatory states can induce alterations in lipid levels and function, so that cholesterol target levels from general guidelines may not be adequate in chronic inflammatory rheumatic diseases. Larger trials are needed to refine the precise benefits and health-utility associated with this therapy.

AB - Chronic inflammatory rheumatic diseases are associated with an increased risk of cardiovascular (CV) atherosclerotic events. The inflammatory state, which is the hallmark of chronic rheumatic diseases, is the important driving force for accelerated atherogenesis. Since the control of traditional risk factors alone is insufficient in reducing the risk, much attention has been directed towards the potential use of statins. Statins, a family of drugs that suppress cholesterol biosynthesis by inhibiting the hydroxymethyl glutaryl coenzyme A reductase, have been shown to significantly reduce CV-related morbidity and mortality. In addition to lower lipid levels, several non-lipid lowering pleiotropic effects, including anti-inflammatory and immunomodulatory activities, make statins potential therapeutic agents in chronic rheumatic diseases. However, lipid metabolism in chronic rheumatic diseases is complex, since inflammatory states can induce alterations in lipid levels and function, so that cholesterol target levels from general guidelines may not be adequate in chronic inflammatory rheumatic diseases. Larger trials are needed to refine the precise benefits and health-utility associated with this therapy.

KW - Cardiovascular risk

KW - Rheumatic diseases

KW - Statins

UR - http://www.scopus.com/inward/record.url?scp=84861473566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861473566&partnerID=8YFLogxK

M3 - Article

C2 - 22507314

AN - SCOPUS:84861473566

VL - 25

SP - 25

EP - 30

JO - International Journal of Immunopathology and Pharmacology

JF - International Journal of Immunopathology and Pharmacology

SN - 0394-6320

IS - 1

ER -